|
|
|
市場調查報告書
全球的骨質疏鬆治療市場
Osteoporosis Therapeutics
|
全球的骨質疏鬆治療市場 是由出版商Global Industry Analysts, Inc.在2011年01月所出版的。
這份英文市場調查報告書包含Pages: 434 價格從美金4500起跳。
本報告書內容包括:全球的骨質疏鬆症治療市場的調查分析、產業的概要、市場的展望、主要藥效分類、市場動態、產品的概要、產品的引進和認定、最近的產業活動、主要企業的概要、全球市場展望、各國市場的概要等彙整、內容綱要摘記如下:
第1章 介紹、調查方法、產品的定義
第2章 展望
- 非專利藥物的流入直擊全球的市場收入
- 新治療帶給市場成長的回復
- Denosumab成為很大的市場機會
- 目前和未來的分析
- 各地區分析
第3章 主要藥效分類
- 雙磷酸鹽類藥物
- 雌激素代償療法
- SERM（選擇性雌激素受體調變器）
- Calcitonins
- 單株抗體（Denosumab）
- 新藥/開發中的藥物
第4章 市場動態
第5章 產品的概要
- 不注意之下所進行的骨質疏鬆症
- 骨質的生理學介紹
- 骨質疏鬆症的進行
- 骨質疏鬆症的主要種類
- 骨質疏鬆症治療的概要
- 主要的骨質疏鬆症藥效分類
第6章 最近的主要臨床實驗和研究結果
第7章 產品的引進和認定
第8章 最近的產品引進和認定
第9章 最近的產業活動
第10章 最近的產業活動：今後的展望
第11章 全球的主要企業
第12章 全球市場的展望
第13章 美國
第14章 日本
第15章 歐洲
競爭企業介紹
Abstract
This report analyzes the worldwide markets for Osteoporosis Therapeutics in
US$ Million by the following major therapeutic classes: Bisphosphonates, ERT
Drugs, SERMs, Calcitonins, and MAB (Denosumab). The report provides separate
comprehensive analytics for the US, Japan, Europe, and Rest of World. Annual
estimates and forecasts are provided for the period 2007 through 2015. Also, a
seven-year historic analysis is provided for these markets. The report
profiles 51 companies including many key and niche players such as Abbott
Laboratories, Eli Lilly and Company, F.Hoffmann-La Roche Ltd, Merck & Co.,
Inc., Novartis AG, Novo Nordisk, Pfizer, Inc., Wyeth, Sanofi-Aventis SA,
Servier SA, Unigene Laboratories, Inc., and Warner Chilcott plc. Market data
and analytics are derived from primary and secondary research. Company
profiles are mostly extracted from URL research and reported select online
sources.
Table of Contents
1. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS 1
- Study Reliability and Reporting Limitations 1
- Disclaimers 2
- Data Interpretation & Reporting Level 3
- Quantitative Techniques & Analytics 3
- Product Definitions and Scope of Study 3
- Bisphosphonates 4
- Hormone Replacement Therapy/Estrogen Replacement Therapy 4
- Estrogens 4
- Estrogens/Progesterones 4
- Calcitonins 4
- Selective Estrogen Receptor Modulators (SERMs) 4
- Other Therapeutics 5
2. OUTLOOK 6
- Generic Incursion Drubs Market Revenues Worldwide 6
- Novel Therapies to Recuperate Market Growth 6
- Denosumab Bodes Significant Market Opportunities 7
- Current and Future Analysis 7
- Analysis By Region 7
- United States 7
- Europe 7
- Japan 8
3. MAJOR THERAPEUTIC CLASSES: A GLOBAL PERSPECTIVE 9
- Bisphosphonates 9
- The leading Therapeutic Market - Only for Now 9
- ERT Drugs 9
- Ups and Downs in the ERT Market 9
- Outlook 9
- SERMs (Selective Estrogen Receptor Modulators) 10
- Calcitonins 10
- Monoclonal Antibodies (Denosumab) 11
- New Drugs/Drug Classes in Pipeline 11
- End-Stage Therapies (Under Development) for Osteoporosis Prevention/Cure
11
- SERMs 12
- Arzoxifene Proves Superior to Evista(r) in Clinical Trials 12
- Fablyn Approval in the US Further Delayed 13
- Bisphosphonates 13
- Zoledronic Acid 13
- Pamidronate 13
- Calcitonin 14
- Parathyroid Hormone (PTH) 14
- Monoclonal Antibodies - Denosumab 14
- Table 1: Comparison of Major Osteoporosis Drugsin Reducing Risk of
Fracture 15
- RANK Ligand 15
- Combination Therapy 15
- Others 15
- Cathepsin K inhibitors 15
- Merck' s Odanacatib Shows Positive Results from Long Term Phase II Study
Data 15
4. MARKET DYNAMICS 17
- Facts & Figures: The Osteoporosis Primacy 17
- Snapshots 17
- Table 2: Prevalence of Osteoporosis and Osteopenia in Major Markets
including US, Germany, Italy, France,UK, Spain and Japan: 2003-2013 (In
Millions)(includes corresponding Graph/Chart) 17
- Osteoporosis Therapeutics: An Evolutionary Scan 17
- Currently Available Drugs for Osteoporosis Treatment 18
- "A Sketch of the Present Industry Scenario" 18
- Factors Influencing Demand 19
- Altering Competitive Landscape in Osteoporosis Market 19
- Table 3: Leading Drugs in the Global Osteoporosis Therapeutics Market
(2006-2009): Value Sales forActonel, Fosamax, Evista, Boniva, Forteo
andAclasta/Reclast in US$ Million (includescorresponding Graph/Chart) 20
- Table 4: Leading Osteoporosis Therapies and itsCost per Day 21
- Market Trends and Issues 21
- Poor Disease Detection - A Major Market Constraint 21
- Reluctance to Undergo HRT to Increase Osteoporosis Burden 21
- Patent Expiries to Impact Market Growth 21
- Limitations Bog Down Current Therapies 22
- Growth Opportunities Galore for New Drugs 22
- Bisphosphonates to Lose Market Value 22
- Poor Compliance Mars Use of Bisphosphonates 23
- Side Effects of HRT Fuel Natural Alternatives Sales 23
- Bone Formation Drugs Augur New Prospects 24
- A Sneak Into Various Options in Antiresorptives, Anabolic Therapeutics
25
- Estrogen Replacement Therapy: Will Dosing Make a Difference? 25
- Is Prevention Always Better Than Cure? 26
- Peptide-Based Osteoporosis Therapy Gaining Ground 26
- Polymorphism- A Potent Diagnostic Marker 26
- Bisphosphonates - The Other Side 26
- Efficacy of Evista Under the Scanner 27
5. PRODUCT OVERVIEW 28
- The "Silent Thief" 28
- An Introduction to Bone Physiology 28
- How Osteoporosis Steps In 28
- Osteoporosis: Major Types 29
- Primary Osteoporosis 29
- Secondary Osteoporosis 29
- Osteoporosis - The Aftermath 30
- Prevention: The Only Better Way Out 30
- Osteoporosis Therapies: A Cursory Glance 31
- Non-drug Therapy 31
- Drug Therapy 31
- Major Osteoporosis Therapeutic Classes: A Brief Review 31
- Bisphosphonates 31
- Classification of Bisphosphonates 32
- Alendronate 32
- Etidronate 32
- Risedronate 32
- Calcitonins: A Relatively Safer Therapeutic 32
- What It Is 32
- What It Does 33
- Major Types 33
- Salmon Calcitonin 33
- SERM: A Breakthrough 33
- Raloxifene: Most Widely Approved SERM 33
- SERMs: The Positive Angle 34
- SERMs: The Negative Side 34
- Hormone Replacement Therapy/Estrogen Replacement Therapy: The
Longstanding Therapeutic 34
- ERT: The Positive Side 34
- The Negative Angle to ERT 35
- Tereparatide: The First Anabolic Agent 35
- Composition 35
- Forteo: A Leading Brand 35
- Major Osteoporosis Therapeutic Classes at a Glance 35
- Osteoporosis Therapeutics: A Peek into the Major Brands 36
6. MAJOR CLINICAL TRIALS/FINDINGS IN RECENT PAST 38
- GSK & NPS Collaborate for Phase II Clinical Study of Calcilytics 38
- Radius Initiates Phase II Trials for BA058 38
- Novartis and Nordic Initiate Phase III Clinical Trial of Oral Salmon
Calcitonin 38
- Medivir Initiates First Human Trials for MIV-701 39
- Osteologix Begins Phase II Trial of NB S101 39
- Zelos and Nektar Initiates Phase I Clinical Trial of Ostabolin-C(tm) 39
- Acceleron Initiates Phase I Clinical Trial of ACE-011 40
- Positive Results from Reclast Clinical Trials 40
7. PRODUCT INTRODUCTIONS/APPROVALS 41
- Pfizer Launches Bazedoxifene in Japan 41
- Daiichi Files for Approval of Denosumab in Japan 41
- Amgen Obtains FDA Approval for Prolia (denosumab) in Treating
Post-Menopausal Osteoporosis 41
- Amgen Obtains EC Approval for Marketing Prolia(r) 42
- Teva to Launch Generic Version of Evista 42
- Eli Lilly Obtains FDA Approval for Expanded Indication of Forteo(r) 42
- WANBURY Introduces a Calcium Brand, CDENSE, in India 43
- Yissum Launches New Compound for Osteoporosis Treatment 43
- Novartis Bags US Approval for Reclast 43
- Wyeth Obtains EC Approval for Conbriza(tm) 43
- Ono and Astellas Introduce Bonoteo in Japan 44
- European Commission Grants Approval to Pfizer for FABLYN(r) Tablets 44
- MDRNA Receives Tentative Approval for New Osteoporosis Drug 44
- Novartis Receives EU Approval for Aclasta 44
- Sun Pharmaceutical Industries Receives Approval for Fosamax (S) 45
- Dr Reddy' s Obtains Approval for Production and Marketing of Generic
Fosamax 45
- Aurobindo Pharma Obtains Approval for Introducing Sodium Tablets in the US
45
- Procter & Gamble Obtains Approval for Actonel 45
- Eli Lilly Obtains European Commission Approval for FORSTEO(r) 45
- Ranbaxy Collaborates with Virchow to Introduce Bonista Teriparatide
Injection 45
- Barr Pharmaceuticals Subsidiary Introduces Generic Osteoporosis Drug 45
- Teva Pharmaceutical Industries Obtains Approval for Generic Fosamax(r)
Tablets 46
8. PRODUCT INTRODUCTIONS/APPROVALS IN THE RECENT PAST - A PERSPECTIVE BUILDER 47
- P&G Receives FDA Approval for New Dosage of Actonel 47
- Takeda Introduces Benet(r) for Osteoporosis Treatment 47
- Labtec Obtains Approval to Market Hormone Replacement Patch in Europe 47
- Wyeth Obtains Conditional Approval for Osteoporosis Drug from FDA 47
- Merck' s New Dosage of FOSAMAX PLUS D Gains FDA Approval 48
- Japanese Pharma Majors Receive Approval for Generic Osteoporosis Drug 48
- Roche and GlaxoSmithKline Introduce Bonviva 49
- GlaxoSmithKline and Roche Co-Promoted Boniva Receives FDA Approval 49
- Nycomed' s Preotact Recommended for Approval in Europe 49
- Procter & Gamble and Sanofi-Aventis' Actonel Approved for Male
Osteoporosis 49
- Upsher-Smith Laboratories Rolls Out Fortical Nasal Spray 50
- Teva Receives Tentative FDA Approval for Risedronate Sodium Tablets 50
- GlaxoSmithKline and Roche Receive Approval for Bonviva in Switzerland 50
- Roche' s Once-a-month Bisphosphonate Gets FDA Nod 51
- Actonel with Calcium(r) Obtains FDA Approval 51
- FDA Approves Unigene' s Nasal Calcitonin 51
- Novavax' s ESTRASORB(r) Clears FDA Hurdle 51
- Menostar(tm) Secures FDA Approval 51
- Bonviva Gains European Commission Approval 52
- Schering Introduces New Hormone Therapy Products 52
- Eli Lilly Launches Evista in Japan and China 52
- Proteolos Bags EU Approval 52
- Forcaltonin(r) Secures European Approval 52
- Ministry of Health Labor and Welfare Approves P&G' s Actonel(r) 52
- Eli Lilly' s Osteoporosis Drug Obtains US Approval 53
- Vivelle Dot 0.025 ERT Patch from Novogyne 53
- Novartis Rolls Out Estradot 53
- Pfizer Launches FemHRT 53
- Ligand Unveils LGD2226 53
9. RECENT INDUSTRY ACTIVITY 54
- Oramed and Laser Detect Systems Ink Joint Venture Agreement 54
- Orchid Chemicals and Pharmaceuticals, and Alvogen Ink Agreement 54
- Abbott Takes Over Solvay Pharmaceuticals 54
- Novartis Obtains Clearance To Continue Clinical Trials on Oral Calcitonin
54
- Merck Merges with Schering-Plough 55
- Warner Chilcott Acquires Pharmaceuticals Business of P&G 55
- Unigene Laboratories Signs Agreement with Tarsa Therapeutics 55
- Bone Medical Obtains Formal Response from FDA for Capsitonin' s IND 55
- US District Court Confirms Validity of Eli Lilly' s Patent for Evista(r) 56
- US District Court Confirms Validity of Unigene' s Patent for Fortical(r) 56
- Ajinomoto Announces Japan Rights for Risedronate Hydrate from P&G 56
- Amgen and GSK Join Forces to Market Denosumab 56
- Galapagos-Lily Collaboration Achieves Milestone in Osteoporosis Treatment
57
- EffRx and Nycomed Sign Licensing Deal for EX101 57
- Pfizer Takes Over Wyeth 58
- Pfizer Obtains Complete Response Letter from US FDA for Lasofoxifene 58
- Wockhardt Signs Agreement with DSM Nutritional for Launch of Bonistein in
India 58
- MorphoSys and Galapagos Form Long-Term Development Alliance 58
- Daiichi Sankyo Establishes Ireland-Based Subsidiary 59
- Merck and Japan Tobacco Sign Global Licensing Agreement for JTT-305 59
- Zelos Therapeutics Signs Agreements for Registration Study of ZT-031 59
- NuVasive Takes Over Osteocal Biologics Business of Osiris Therapeutics 60
- Eli Lilly and TransPharma Medical Sign Licensing and Development Agreement
60
- Bone Medical Joins Hands with Hyundai Pharm. for Marketing PTH in South
Korea 60
- Eli Lilly to Acquire Osteoporosis Drug Patch from TransPharma Medical 60
- Wyeth Obtains Approvable Letter from FDA for Bazedoxifene 61
- Daiichi Sankyo Establishes Subsidiary in Turkey 61
- Aegis Therapeutics and Zelos Therapeutics Sign Agreement for ZT-031 61
- Teijin Pharma Obtains a License from Dong Wha Pharm for DW-1350 61
- IOF Signs Agreements with Chinese Organizations for Osteoporosis Treatment
62
- DAIICHI SANKYO Takes Over EVISTA(r) from Eli Lilly 62
10. INDUSTRY ACTIVITY IN THE RECENT PAST - A PERSPECTIVE BUILDER 63
- Daiichi Sankyo Acquires Developing and Marketing Rights for Denosumab in
Japan 63
- Schering-Plough Acquires Organon BioSciences 63
- Faes Farma Signs Marketing Agreement with Roche and GlaxoSmithKline 63
- Alethia and Emerillon Collaborate on Osteoporosis Therapies 64
- Ipsen Enters into Co-marketing Agreement with MSD 64
- Unigene Enters into Agreement with Novartis 64
- Pharming Group Granted Subsidies to Develop Osteoporosis Drugs 64
- Procter & Gamble Terminates Nasal Spray Collaboration with Nastech
Pharmaceutical 65
- Pharming Group Acquires DNage 65
- Amgen Acquires Abgenix 65
- P&G Licenses Osteoporosis Nasal Spray Rights from Nastech 65
- Eli Lilly to Close Basingstoke Plant 66
- Galapagos Acquires Drug Discovery Platform of Discovery Partners 66
- Duravest Acquires Bio-Magnetic Therapy 67
- Galapagos Acquires ProStrakan' s ProSkelia 67
- Roche Inks a Marketing Agreement with Elder Pharma 67
- Chugai and Taisho Sign a Joint Development and Marketing Agreement 67
- Theragenex Signs a Licensing Agreement with Zylera 68
- Radius Acquires Licensing Agreement for Eisai' s SERMs 68
- Alkermes Partners with Eli Lilly to Develop and Market PTH Formulation 68
- Radius Acquires Exclusive Rights to Karo Bio' s SARMS 69
- Unigene Enters into Agreement with Tzamal Bio 69
- Galapagos Acquires Inpharmatica 69
- Bio-Rad Acquires Provalis Medical Diagnostics Operations 69
- Daiichi Sankyo to Market Evista in Europe 70
- Biocon Acquires Nobex 70
- Radius and Ipsen Enters into Licensing Agreement 70
- Novartis Acquires Hexal AG 71
- Nippon Chemiphar Signs Agreement with Velcura Therapeutics 71
- Biopotential Capital Acquires Osta Biopharma 71
- Dnage Commences DNA Research Programme for Osteoporosis Therapeutics 71
- Nastech Initiates Phase I Study of PTH 1-34 71
- SEQUENOM Collaborates with P&G Pharmaceuticals 72
- Novartis Extends Alliance with Emisphere 72
- Eli Lilly Markets Forteo in Europe 72
- Avesthagen Co-develops Osteoporosis Drug with CCBR 72
- Nastech Signs Agreement with Par Pharmaceutical, Inc 72
- Unigene and Novartis in a Licensing and Manufacturing Agreement 72
- Wyeth Ties Up with Tanox and Galapagos 73
- Galapagos and P&G Collaborate to Develop Osteoporosis Drugs 73
- Unigene Grants License to Faran 73
- Genome Collaborates with Amgen 73
- Unigene Joins Hands with Shijiazhuang 73
- Unigene, GSK Signs License Collaboration 74
- Unigene and Upsher-Smith in a Licensing Agreement 74
- Celgene and Novartis Embark on Joint Research for SERMs 74
- Roche, GSK Signs Global Agreement 74
- Novogyne Procures CombiPatch(tm) from Aventis 75
11. FOCUS ON SELECT GLOBAL PLAYERS 76
- Abbott Laboratories (US) 76
- Eli Lilly and Company (US) 76
- F.Hoffmann-La Roche Ltd (Switzerland) 76
- Merck & Co., Inc. (US) 76
- Novartis AG (Switzerland) 77
- Novo Nordisk A/S (Denmark) 77
- Pfizer, Inc. (US) 77
- Sanofi-Aventis SA (France) 78
- Servier SA (France) 78
- Unigene Laboratories, Inc. (US) 79
- Warner Chilcott plc (Ireland) 79
12. GLOBAL MARKET PERSPECTIVE 80
- Table 5: World Recent Past, Current & Future Analysisfor Osteoporosis
Therapeutics by Geographic Region -US, Japan, Europe, and Rest of World
MarketsIndependently Analyzed with Annual Sales Figuresin US$ Million for
Years 2007 through 2015(includes corresponding Graph/Chart) 80
- Table 6: World Historic Review for OsteoporosisTherapeutics by Geographic
Region - US, Japan,Europe, and Rest of World Markets IndependentlyAnalyzed
with Annual Sales Figures in US$ Millionfor Years 2000 through 2006
(includescorresponding Graph/Chart) 81
- Table 7: World 11-Year Perspective for Osteoporosis Therapeutics by
Geographic Region - PercentageBreakdown of Dollar Sales for US, Japan,
Europe,and Rest of World Markets for Years 2005, 2010 & 2015(includes
corresponding Graph/Chart) 82
- Table 8: World Recent Past, Current & Future Analysisfor
Bisphosphonates by Geographic Region - US, Japan,Europe, and Rest of World
Markets IndependentlyAnalyzed with Annual Sales Figures in US$ Millionfor
Years 2007 through 2015 (includescorresponding Graph/Chart) 83
- Table 9: World Historic Review for Bisphosphonatesby Geographic Region -
US, Japan, Europe, andRest of World Markets Independently Analyzed withAnnual
Sales Figures in US$ Million for Years 2000through 2006 (includes
corresponding Graph/Chart) 84
- Table 10: World 11-Year Perspective for Bisphosphonatesby Geographic
Region - Percentage Breakdown ofDollar Sales for US, Japan, Europe, and Rest
of WorldMarkets for Years 2005, 2010 & 2015 (includescorresponding
Graph/Chart) 85
- Table 11: World Recent Past, Current & Future Analysisfor ERT Drugs by
Geographic Region - US, Japan, Europe,and Rest of World Markets Independently
Analyzed withAnnual Sales Figures in US$ Million for Years 2007through 2015
(includes corresponding Graph/Chart) 86
- Table 12: World Historic Review for ERT (Estrogen Replacement Therapy)
Drugs by Geographic Region - US, Japan, Europe,and Rest of World Markets
Independently Analyzed withAnnual Sales Figures in US$ Million for Years
2000through 2006 (includes corresponding Graph/Chart) 87
- Table 13: World 11-Year Perspective for ERT (Estrogen Replacement
Therapy)Drugs by Geographic Region -Percentage Breakdown of Dollar Sales for
US, Japan,Europe, and Rest of World Markets for Years 2005,2010 & 2015
(includes corresponding Graph/Chart) 88
- Table 14: World Recent Past, Current & Future Analysis for SERMs by
Geographic Region - US, Japan, Europe, andRest of World Markets Independently
Analyzed withAnnual Sales Figures in US$ Million for Years 2007through 2015
(includes corresponding Graph/Chart) 89
- Table 15: World Historic Review for SERMs (SelectiveEstrogen Receptors
Modulators) by Geographic Region -US, Japan, Europe, and Rest of World
MarketsIndependently Analyzed with Annual Sales Figuresin US$ Million for
Years 2000 through 2006(includes corresponding Graph/Chart) 90
- Table 16: World 11-Year Perspective for SERMs (Selective Estrogen
Receptors Modulators) by Geographic Region - Percentage Breakdown of Dollar
Sales for US, Japan,Europe, and Rest of World Markets for Years 2005,2010
& 2015 (includes corresponding Graph/Chart) 91
- Table 17: World Recent Past, Current & Future Analysisfor Calcitonins
by Geographic Region - US, Japan, Europe,and Rest of World Markets
Independently Analyzed withAnnual Sales Figures in US$ Million for Years
2007through 2015 (includes corresponding Graph/Chart) 92
- Table 18: World Historic Review for Calcitonins byGeographic Region - US,
Japan, Europe, and Rest of WorldMarkets Independently Analyzed with Annual
SalesFigures in US$ Million for Years 2000 through 2006(includes corresponding
Graph/Chart) 93
- Table 19: World 11-Year Perspective for Calcitonins by Geographic Region -
Percentage Breakdown of DollarSales for US, Japan, Europe, and Rest of World
Marketsfor Years 2005, 2010 & 2015 (includes corresponding Graph/Chart) 94
- Table 20: World Recent Past, Current & Future Analysisfor MAB
(Denosumab) by Geographic Region - US, Japan, Europe, and Rest of World
Markets Independently Analyzedwith Annual Sales Figures in US$ Million for
Years 2007through 2015 (includes corresponding Graph/Chart) 95
- Table 21: World 11-Year Perspective for MAB (Denosumab)by Geographic
Region - Percentage Breakdown of DollarSales for US, Japan, Europe, and Rest
of World Marketsfor Years 2005, 2010 & 2015 (includes corresponding
Graph/Chart) 96
13. THE UNITED STATES 97
- A. Market Analysis 97
- Industry Overview 97
- Outlook 97
- Osteoporosis in the US: An Insight 97
- Osteoporosis - An Underserved Market? 97
- Statistical Review 98
- Table 22: Incidence of Osteoporosis in the US(2004) (includes
corresponding Graph/Chart) 98
- Table 23: Osteoporosis Prevalence inPost-Menopause Women
(includescorresponding Graph/Chart) 99
- Table 24: Number of Osteoporosis PatientsUndergoing Osteoporosis
Therapies (In Thousands) (includes corresponding Graph/Chart) 100
- Osteoporosis Prescription Market 100
- Table 25: US Osteoporosis Prescription Market(2004-2006): Percentage
Share of Leading Drugs- Fosamax, Actonel, Evista, Boniva, Forteo andOthers
(includes corresponding Graph/Chart) 100
- Competitive Scenario 101
- Table 26: Leading Players in the US OsteoporosisMarket (2004 - A
Historic Perspective) - Market Shareby Value Sales for Merck, Eli Lilly,
Procter & Gamble/ Sanofi-Aventis, and Others (includes
correspondingGraph/Chart) 101
- Competitive Review by Segment - A Recent Past Perspective 101
- Bisphosphonates 101
- Table 27: Leading Players in the US Bisphosphonates Market (2004) -
Market Share by Value Sales forMerck and Procter & Gamble/
Sanofi-Aventis 102
- SERMs 102
- Calcitonins 102
- Patent Expiry of Major Osteoporosis Drugs 102
- B. Market Analytics 103
- Table 28: The US Recent Past, Current & Future MarketAnalysis for
Osteoporosis Therapeutics by Product Group - Bisphosphonates, ERT Drugs,
SERMs, Calcitonins, MAB (Denosumab) and Others Independently Analyzed with
Annual Sales Figures in US$ Million for Years 2007through 2015 (includes
corresponding Graph/Chart) 103
- Table 29: US Historic Review for OsteoporosisTherapeutics by Product
Group - Bisphosphonates,ERT Drugs, SERMs, Calcitonins and
OthersIndependently Analyzed with Annual SalesFigures in US$ Million for
Years 2000 through2006 (includes corresponding Graph/Chart) 104
- Table 30: US 11-Year Perspective for Osteoporosis Therapeutics by
Product Group - PercentageBreakdown of Dollar Sales for Bisphosphonates,ERT
Drugs, SERMs, Calcitonins, MAB (Denosumab)and Others for Years 2005, 2010
& 2015 (includescorresponding Graph/Chart) 105
14. JAPAN 106
- Market Analysis 106
- Table 31: Japanese Recent Past, Current & FutureMarket Analysis for
Osteoporosis Therapeutics byProduct Groups - Bisphosphonates, ERT Drugs,
SERMs, Calcitonins and MAB (Denosumab)IndependentlyAnalyzed with Annual
Sales Figures in US$ Millionfor Years 2007 through 2015
(includescorresponding Graph/Chart) 106
- Table 32: Japanese Historic Review for Osteoporosis Therapeutics by
Product Group - Bisphosphonates,ERT Drugs, SERMs, and Calcitonins
IndependentlyAnalyzed with Annual Sales Figures in US$ Millionfor Years 2000
through 2006 (includescorresponding Graph/Chart) 107
- Table 33: Japanese 11-Year Perspective for Osteoporosis Therapeutics by
Product Group - Percentage Breakdownof Dollar Sales for Bisphosphonates, ERT
Drugs,SERMs, Calcitonins and MAB (Denosumab)for Years 2005, 2010 & 2015
(includescorresponding Graph/Chart) 108
15. EUROPE 109
- A. Market Analysis 109
- Outlook 109
- Forteo: The First Anabolic Agent in Europe 109
- European Regulatory Restricts HRT 109
- Calcitonin Embraces New Label 110
- Table 34: European Market for OsteoporosisTherapeutics (2005- A Recent
Past Review): MarketShare of Leading Players - Novartis, Merck, Wyeth,Novo
Nordisk, Organon, Procter & Gamble, Schering, Solvay and Others
(includes correspondingGraph/Chart) 110
- B. Market Analytics 111
- Table 35: European Recent Past, Current & FutureMarket Analysis for
Osteoporosis Therapeutics by Geographic Region - France, Germany, The UK,
Italy, Spain, and Rest of Europe Markets IndependentlyAnalyzed with Annual
Sales Figures in US$ Millionfor Years 2007 through 2015
(includescorresponding Graph/Chart) 111
- Table 36: European Historic Review for Osteoporosis Therapeutics by
Geographic Region - France, Germany,The UK, Italy, Spain, and Rest of Europe
Markets Independently Analyzed with Annual Sales Figuresin US$ Million for
Years 2000 through 2006(includes corresponding Graph/Chart) 112
- Table 37: European 11-Year Perspective for Osteoporosis Therapeutics by
Geographic Regions - Percentage Breakdown of Dollar Sales for France,
Germany,The UK, Italy, Spain, and Rest of Europe Marketsfor Years 2005, 2010
& 2015 (includescorresponding Graph/Chart) 113
- Table 38: European Recent Past, Current & FutureMarket Analysis for
Osteoporosis Therapeutics byProduct Groups - Bisphosphonates, ERT
Drugs,SERMs, Calcitonins and MAB (Denosumab) Independently Analyzed with
Annual Sales Figures in US$ Millionfor Years 2007 through 2015
(includescorresponding Graph/Chart) 114
- Table 39: European Historic Review for Osteoporosis Therapeutics by
Product Group - Bisphosphonates,ERT Drugs, SERMs, and Calcitonins
IndependentlyAnalyzed with Annual Sales Figures in US$ Millionfor Years 2000
through 2006 (includescorresponding Graph/Chart) 115
- Table 40: European 11-Year Perspective forOsteoporosis Therapeutics by
Product Group -Percentage Breakdown of Dollar Sales forBisphosphonates, ERT
Drugs, SERMs, Calcitoninsand MAB (Denosumab) for Years 2005, 2010 &2015
(includes corresponding Graph/Chart) 116
15a. FRANCE 117
- Market Analysis 117
- Table 41: French Recent Past, Current & Future Market Analysis for
Osteoporosis Therapeutics by ProductGroups - Bisphosphonates, ERT Drugs,
SERMs, and Calcitonins Independently Analyzed with Annual SalesFigures in
US$ Million for Years 2007 through 2015(includes corresponding Graph/Chart)
117
- Table 42: French Historic Review for Osteoporosis Therapeutics by
Product Group - Bisphosphonates,ERT Drugs, SERMs, and Calcitonins
IndependentlyAnalyzed with Annual Sales Figures in US$ Millionfor Years 2000
through 2006 (includescorresponding Graph/Chart) 118
- Table 43: French 11-Year Perspective for Osteoporosis Therapeutics by
Product Group - PercentageBreakdown of Dollar Sales for Bisphosphonates,ERT
Drugs, SERMs, and Calcitonins for Years2005, 2010 & 2015 (includes
correspondingGraph/Chart) 118
15b. GERMANY 119
- Market Analysis 119
- Table 44: German Recent Past, Current & FutureMarket Analysis for
Osteoporosis Therapeutics byProduct Groups - Bisphosphonates, ERT
Drugs,SERMs, and Calcitonins Independently Analyzedwith Annual Sales Figures
in US$ Million forYears 2007 through 2015 (includescorresponding
Graph/Chart) 119
- Table 45: German Historic Review for Osteoporosis Therapeutics by
Product Group - Bisphosphonates,ERT Drugs, SERMs, and Calcitonins
IndependentlyAnalyzed with Annual Sales Figures in US$ Millionfor Years 2000
through 2006 (includescorresponding Graph/Chart) 120
- Table 46: German 11-Year Perspective forOsteoporosis Therapeutics by
Product Group -Percentage Breakdown of Dollar Sales forBisphosphonates, ERT
Drugs, SERMs, andCalcitonins for Years 2005, 2010 & 2015(includes
corresponding Graph/Chart) 120
15c. THE UNITED KINGDOM 121
- A. Market Analysis 121
- Osteoporosis Population in the UK: 2004 -2009 121
- B. Market Analytics 122
- Table 47: UK Recent Past, Current & Future MarketAnalysis for
Osteoporosis Therapeutics by ProductGroups - Bisphosphonates, ERT Drugs,
SERMs,and Calcitonins Independently Analyzed withAnnual Sales Figures in US$
Million for Years2007 through 2015 (includes correspondingGraph/Chart) 122
- Table 48: UK Historic Review for OsteoporosisTherapeutics by Product
Group - Bisphosphonates,ERT Drugs, SERMs, and Calcitonins
IndependentlyAnalyzed with Annual Sales Figures in US$ Millionfor Years 2000
through 2006 (includescorresponding Graph/Chart) 123
- Table 49: UK 11-Year Perspective for Osteoporosis Therapeutics by
Product Group - Percentage Breakdownof Dollar Sales for Bisphosphonates, ERT
Drugs, SERMs, and Calcitonins for Years 2005, 2010 & 2015(includes
corresponding Graph/Chart) 123
15d. ITALY 124
- Market Analysis 124
- Table 50: Italian Recent Past, Current & FutureMarket Analysis for
Osteoporosis Therapeutics byProduct Groups - Bisphosphonates, ERT
Drugs,SERMs, and Calcitonins Independently Analyzedwith Annual Sales Figures
in US$ Millionfor Years 2007 through 2015 (includescorresponding
Graph/Chart) 124
- Table 51: Italian Historic Review for Osteoporosis Therapeutics by
Product Group - Bisphosphonates,ERT Drugs, SERMs, and Calcitonins
IndependentlyAnalyzed with Annual Sales Figures in US$ Millionfor Years 2000
through 2006 (includescorresponding Graph/Chart) 125
- Table 52: Italian 11-Year Perspective for Osteoporosis Therapeutics by
Product Group - PercentageBreakdown of Dollar Sales for Bisphosphonates,ERT
Drugs, SERMs, and Calcitonins forYears 2005, 2010 & 2015
(includescorresponding Graph/Chart) 125
15e. SPAIN 126
- Market Analysis 126
- Table 53: Spanish Recent Past, Current & FutureMarket Analysis for
Osteoporosis Therapeutics byProduct Groups - Bisphosphonates, ERT
Drugs,SERMs, and Calcitonins Independently Analyzedwith Annual Sales Figures
in US$ Million forYears 2007 through 2015 (includescorresponding
Graph/Chart) 126
- Table 54: Spanish Historic Review for Osteoporosis Therapeutics by
Product Group - Bisphosphonates,ERT Drugs, SERMs, and Calcitonins
IndependentlyAnalyzed with Annual Sales Figures in US$ Millionfor Years 2000
through 2006 (includescorresponding Graph/Chart) 127
- Table 55: Spanish 11-Year Perspective for Osteoporosis Therapeutics by
Product Group - PercentageBreakdown of Dollar Sales for Bisphosphonates,ERT
Drugs, SERMs, and Calcitonins forYears 2005, 2010 & 2015
(includescorresponding Graph/Chart) 127
15f. REST OF EUROPE 128
- A. Market Analysis 128
- B. Market Analytics 129
- Table 56: Rest of Europe Recent Past, Current &Future Analysis for
Osteoporosis by Product Groups - Bisphosphonates, ERT Drugs, SERMs,
andCalcitonins Independently Analyzed withAnnual Sales Figures in US$
Million for Years2007 through 2015 (includes correspondingGraph/Chart) 129
- Table 57: Rest of Europe Historic Review forOsteoporosis Therapeutics
by Product Groups - Bisphosphonates, ERT Drugs, SERMs, and Calcitonins
Independently Analyzed with Annual Sales Figuresin US$ Million for Years
2000 through 2006(includes corresponding Graph/Chart) 130
- Table 58: Rest of Europe 11-Year Perspective for Osteoporosis
Therapeutics by Product Group -Percentage Breakdown of Dollar Sales
forBisphosphonates, ERT Drugs, SERMs, andCalcitonins for Years 2005, 2010
& 2015(includes corresponding Graph/Chart) 131
16. REST OF WORLD 132
- A. Market Analysis 132
- Outlook 132
- Prevalence of Osteoporosis in Various Region-At a Glance 132
- Korea 133
- Table 59: Korean Osteoporosis Therapeutics Marketby Leading Brands
(2005 - A Recent Past Perspective): Percentage Share Breakdown by Dollar
Sales forFosamax, Atonel, Alend, Maxmarvil, and Others(includes
corresponding Graph/Chart) 133
- China 133
- B. Market Analytics 134
- Table 60: Rest of World Recent Past, Current &Future Analysis for
Osteoporosis Therapeutics byProduct Groups - Bisphosphonates, ERT
Drugs,SERMs, Calcitonins and MAB (Denosumab)Independently Analyzed with
Annual Sales Figuresin US$ Million for Years 2007 through 2015(includes
corresponding Graph/Chart) 134
- Table 61: Rest of World Historic Review forOsteoporosis Therapeutics by
Product Groups - Bisphosphonates, ERT Drugs, SERMs, andCalcitonins
Independently Analyzed withAnnual Sales Figures in US$ Million for Years2000
through 2006 (includes correspondingGraph/Chart) 135
- Table 62: Rest of World 11-Year Perspective forOsteoporosis
Therapeutics by Product Group -Percentage Breakdown of Dollar Sales
forBisphosphonates, ERT Drugs, SERMs, Calcitoninsand MAB (Denosumab) for
Years 2005, 2010 &2015 (includes corresponding Graph/Chart) 136
- Total Companies Profiled: 51 (including Divisions/Subsidiaries -
67)Region/Country PlayersThe United States 29 Canada 4
- Japan 7
- Europe 20
- France 3
- Germany 3
- The United Kingdom 3
- Italy 2
- Spain 1
- Rest of Europe 8
- Asia-Pacific (Excluding Japan) 5
COMPETITIVE LANDSCAPE
|
 |
